Whereas vonapanitase did not meet its primary end point, there were several clinically meaningful indicators that vonapanitase may be an effective therapy in fistula creation. Importantly, vonapanitase was associated with increases in secondary patency and use of the fistula for hemodialysis.
I would have said the same as before. I think the scientific basis was very weak on this one and it seems the story is now over.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.